Concentra Group Holdings delivered robust performance in the second quarter of 2025, with revenue increasing by 15.2% to $550.8 million and Adjusted EBITDA growing by 13.2% to $115.0 million. The company saw a 9.5% increase in patient visits per day and a 4.4% rise in revenue per visit. Net income was $46.2 million, and Adjusted EPS was $0.37. The company also successfully integrated recent acquisitions, expanding its network to over 1,000 locations.
Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter, driven by organic and inorganic growth, including the acquisition of Nova Medical Centers and the launch of new de novo centers.
Concentra reported preliminary unaudited financial results for Q4 2024, with revenue increasing by 5.5% over Q4 2023 and Adjusted EBITDA increasing by 13.6%. The company also announced a definitive agreement to acquire Nova Medical Centers and provided its preliminary 2025 business outlook.
Concentra Group Holdings reported a revenue increase of 2.3% to $477.9 million, with operating income up by 2.2% to $83.9 million. Net income saw a slight decrease of 1.8% to $53.1 million. The company also completed its IPO, marking a significant milestone.